CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis

Journal of Cellular and Molecular Medicine

Chunguang Guo¹  Long Liu²  Yuling Sun³  Libo Wang³  Dechao Jiao⁴  Zaoqu Liu⁴  Xinwei Han⁴  Lifeng Li⁵  Jie Zhao⁶ 

[1] Department of Endovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, China;Zhengzhou Basic and Clinical Key Laboratory of Hepatopancreatobiliary Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Internet Medical and System Applications of National Engineering Laboratory, Zhengzhou, China;Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Internet Medical and System Applications of National Engineering Laboratory, Zhengzhou, China;Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;

关键词: CELF2;    immune infiltration;    immunotherapy;    lung squamous cell carcinoma;    prognosis;    triple‐negative breast cancer;   

DOI  :  10.1111/jcmm.16791

来源: Wiley

【 授权许可】

CC BY